Janssen Receives Positive CHMP Opinions for Novel
Talquetamab is the first therapy targeting GPRC5D to receive a positive CHMP Opinion Teclistamab, the first BCMA-targeting bispecific antibody to...
Source: globenewswire.com
Page 3 - Escalation Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Escalation Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Escalation Study Today - Breaking & Trending Today
Janssen Presents Longer-Term Data for TECVAYLI® (teclistamab-cqyv) Showing a Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple Myeloma
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today long-term data from the pivotal Phase 1/2 MajesTEC-1 study showing...
Source: prnewswire.com
Janssen Presents Longer-Term Talquetamab Follow-Up Data
Additional long-term data from the TRiMM-2 study in patients receiving talquetamab and DARZALEX® (daratumumab) subcutaneous (SC) formulation combination...
Source: globenewswire.com
Affimed Announces Abstracts at the Annual Meeting of the European Hematology Association
A post-hoc subgroup analysis from the AFM13 REDIRECT study in patients with relapsed/refractory peripheral T cell lymphoma is accepted as a poster presentationA trial in progress abstract of the... | May 11, 2023
Source: marketscreener.com
Janssen Presents First Data from MajesTEC-2 Trial of
Initial Phase 1b study results show clinical activity with immune-based triplet therapy regimen1 BEERSE, Belgium, Dec. 10, 2022 (GLOBE NEWSWIRE) -- The...
Source: globenewswire.com